AI in Precision Medicine Market to Reach US$ 32.41 Billion by 2033, Driven by Breakthroughs in Genomics and Personalized Treatment

According to DataM Intelligence, the Global AI in Precision Medicine Market was valued at US$ 1,703.19 million in 2024 and is projected to reach US$ 32,410 million by 2033, expanding at a remarkable CAGR of 38.7% during the forecast period (2025-2033). Artificial Intelligence (AI) in precision medicine integrates computational analytics, machine learning, and big data processing to customize medical care for individual patients. It plays a pivotal role in genomics, diagnostics, and clinical decision-making by analyzing large datasets from multi-omics and clinical records to derive actionable insights for targeted therapies.

Get a Free Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.datamintelligence.com/download-sample/oncology-clinical-trials-market?utm_source=OpenPR&utm_campaign=Onkar

The market is being driven by the rising global burden of chronic and life-threatening diseases, expanding applications in oncology and neurology, and rapid digitalization in healthcare ecosystems. North America currently holds the largest share due to advanced R&D infrastructure and AI adoption across medical research sectors. Meanwhile, Asia-Pacific is the fastest-growing region, fueled by large health data repositories, genomic research programs, and government-backed precision healthcare initiatives in countries like China, Japan, and India.

Key Highlights from the Report

➤ Market expected to surge from US$ 1.7 billion in 2024 to US$ 32.41 billion by 2033 at 38.7% CAGR.
➤ Software segment leads with over 35% share, dominated by AI algorithms and data analytics platforms.
➤ North America remains the largest market; Asia-Pacific emerging as fastest-growing region.
➤ Oncology and neurology are major applications, driven by AI-powered diagnostic and predictive tools.
➤ Collaborations among tech and healthcare companies-like Illumina and Tempus AI-accelerate genomic innovations.
➤ Growing integration of generative AI, NLP, and predictive modeling optimizes drug discovery and patient management.

Market Segmentation

The global AI in precision medicine market is segmented by technology, component, application, and region.

Component: Software Dominates Market Share
The software segment, valued at US$ 638.53 million in 2024, is projected to reach US$ 1,366.36 million by 2033, growing at a CAGR of over 32%. AI-based software systems help analyze multi-omic and clinical data for precise disease profiling, biomarker identification, and real-time patient monitoring. Advanced analytical software like machine learning (ML) platforms and Natural Language Processing (NLP) tools enable predictive modeling and personalized treatment customization. The launch of OM1's AI phenotyping tools (May 2024)-Orion, Lyra, and Polaris-reflects the surge in demand for clinically actionable decision-support software in global healthcare institutions.

Application: Oncology and Neurology at the Forefront
Oncology remains the largest application in AI-driven precision medicine due to the technology's success in early cancer detection, genomic sequencing, and precision drug design. AI enables rapid analysis of tumor profiles and assists clinicians in predicting patient response to therapies. Similarly, neurology applications are expanding, supported by partnerships like the 2024 collaboration between Siemens Healthineers and IISc India, focused on AI-enhanced neuroimaging diagnostics using open-source algorithms for brain pathology analysis.

Get Customization in the Report as Per Your Business Requirements: https://www.datamintelligence.com/customize/oncology-clinical-trials-market?utm_source=OpenPR&utm_campaign=Onkar

Regional Insights

North America: Market Leader

North America accounted for US$ 730.02 million in 2024, projecting continued dominance with a CAGR of 36%-38% through 2033. The region benefits from strong integration of EHR databases, AI-driven R&D, and major corporate collaborations. Companies like Google Health, Tempus, and PathAI lead AI-enabled drug discovery and clinical trials. Regulatory clarity from the U.S. FDA on AI/ML medical applications also fosters rapid market approval for AI technologies. The 2025 partnership between Precision for Medicine and PathAI to enhance AI-powered biomarker analysis and clinical trials exemplifies ongoing innovation.

Asia-Pacific: Fastest-Growing Market

The Asia-Pacific market is advancing at a CAGR of 40%-42%, reaching US$ 360.95 million in 2024. Countries like Japan, China, and India are leveraging sovereign AI systems and precision medicine platforms for patient stratification and national genomics databases. Notably, SoftBank and Tempus' joint venture (SB TEMPUS Corp) aims to deliver real-time AI precision medicine platforms across Japan. Additionally, companies like iCarbonX in China are pioneering integrations of genomics, lifestyle, and environmental datasets to produce individualized health profiles.

Market Dynamics

Market Drivers

Breakthroughs in AI algorithms and machine learning are transforming personalized healthcare by enabling faster and more accurate processing of genomic and proteomic data. Advanced computational tools are improving early disease detection, drug design, and optimized treatment protocols, particularly in oncology and cardiology.

Market Restraints

Data privacy and security issues pose challenges to adoption. The use of vast patient datasets raises concerns about unauthorized data access and regulatory inconsistencies. Without standardized oversight, privacy breaches could impede both patient trust and global scale-up.

Market Opportunities

Rising collaborations between biotechnology, AI, and clinical research firms open new opportunities for precision drug development, clinical trial optimization, and real-world data integration. Continuous AI innovation through generative models and predictive analytics ensures ongoing potential in disease management, genomics, and therapeutics.

Purchase This Exclusive Report at Just USD 4450 Only: https://www.datamintelligence.com/buy-now-page?report=oncology-clinical-trials-market?utm_source=OpenPR&utm_campaign=Onkar

Reasons to Buy the Report

✔ In-depth analysis of technological advancements and key trends shaping the AI in precision medicine market.
✔ Detailed segmentation insights by technology, component, and application.
✔ Comprehensive coverage of regional growth opportunities and competitive strategies.
✔ Evaluation of emerging collaborations among healthcare, AI, and genomics leaders.
✔ Market forecasts up to 2033 highlighting adoption drivers and regulatory considerations.

Frequently Asked Questions (FAQs)

◆ How big is the AI in Precision Medicine Market in 2024?
◆ What is the projected CAGR of the AI in Precision Medicine Market from 2025 to 2033?
◆ Which region leads the global AI in precision medicine market?
◆ What are the key technology trends driving AI in precision healthcare?
◆ Which companies are major players in the AI in precision medicine industry?

Company Insights
IBM Corporation

Microsoft Corporation

AstraZeneca

Sanofi

GE Healthcare

Intel Corporation

NVIDIA Corporation

Alphabet Inc.

BioXcel Therapeutics Inc.

Illumina Inc.

Recent Developments

April 2025: Illumina Inc. and Tempus AI, Inc. announced a strategic collaboration to combine NGS and multimodal data analytics to accelerate genomic algorithm development.

January 2025: Guardant Health and ConcertAI launched the first integrated multi-modal real-world data (RWD) platform, merging EMR data with genomic and epigenomic profiles across cancer care.

Conclusion
The Global AI in Precision Medicine Market is poised for exponential growth as healthcare shifts toward data-driven, individualized treatment paradigms. While challenges around privacy and interoperability remain, rapid integration of generative AI, real-world evidence, and predictive model analytics is redefining medical research and patient care. North America continues to lead innovation, while Asia-Pacific's digital transformation signals the next wave of precision medicine advancements globally. By 2033, AI will play a transformative role in clinical diagnostics, drug personalization, and predictive medicine, reshaping the future of global healthcare.

Contact Us

Mr. Sai Kiran
DataM Intelligence 4market Research LLP Ground floor
DSL Abacus IT Park, Industrial Development Area
Uppal, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com
Visit Our Website: https://www.datamintelligence.com

About Us

DataM Intelligence 4Market Research is a comprehensive market intelligence platform offering syndicated and customized reports along with expert consulting across multiple industries, including chemicals, healthcare, agriculture, food & beverages, and more. With extensive experience and a strategy-focused approach, DataM provides businesses and individuals with reliable market insights, statistical forecasts, and personalized research solutions to help them make informed decisions and successfully bring innovations to market.

This release was published on openPR.